Sun Pharma numbers were slightly below expectations in terms of EBITDA and we do think that though they have guided for a very strong growth through their speciality portfolio, that is a little bit time away.
Politics may trump macros in 2026 US rate cycle: Rajeev Agrawal
Recent US economic data shows inflation and jobless claims are lower than anticipated. However, a government shutdown may have skewed these figures. Experts suggest clarity